Role of ceramides in barrier function of healthy and diseased skin

American Journal of Clinical Dermatology

Volumn 6, Issue 4, 2005, Pages 215-223

  Choi, Myeong Jun ^a,b   Maibach, Howard I ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Charmzone Co LTD   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLSPHINGOSINE DEACYLASE; BIOLOGICAL MARKER; CERAMIDE; GLUCOSYLCERAMIDE DEACYLASE; ISOENZYME; PROSAPOSIN; SKIN LIPID; SPHINGOLIPID ACTIVATOR PROTEIN; SPHINGOMYELIN DEACYLASE; UNCLASSIFIED DRUG;

ATOPIC DERMATITIS; CERAMIDE DEFICIENCY; CONTACT DERMATITIS; DRUG POTENCY; ENZYME ACTIVITY; EPIDERMIS; FARBER DISEASE; GAUCHER DISEASE; GENETIC DISORDER; HOMEOSTASIS; HUMAN; LIPID ANALYSIS; LIPID COMPOSITION; LIPID DEGRADATION; LIPOGENESIS; NIEMANN PICK DISEASE; NUTRITIONAL DEFICIENCY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; REVIEW; SKIN DISEASE; SKIN FUNCTION; SKIN PERMEABILITY; STRATUM CORNEUM; SUPPLEMENTATION; TISSUE LEVEL;

ADMINISTRATION, TOPICAL; CERAMIDES; HUMANS; SKIN DISEASES; SKIN PHYSIOLOGY; SPHINGOLIPIDOSES;

EID: 23844476054     PISSN: 11750561     EISSN: 11750561     Source Type: Journal    
DOI: 10.2165/00128071-200506040-00002     Document Type: Review

References (62)

1. Bouwstra JA, Honeywell-Nguyen PL, Gooris GS, et al. Structure of the skin barrier and its modulation by vesicular formulations. Prog Lipid Res 2003; 42: 1-36
2. Imokawa G, Abe A, Jin K, et al. Decreased level of ceramides in stratum corneum of atopic dermatitis: an etiologic factor in atopic dry skin. J Invest Dermatol 1991; 96: 523-6
3. Paige DG, Morse-Fisher N, Harper JI. Quantification of stratum corneum ceramides and lipid envelope ceramides in the hereditary ichthyoses. Br J Dermatol 1994; 131: 23-7
4. Matsumoto M, Umemoto N, Sugiura H, et al. Difference in ceramide composition between "dry" and "normal" skin in patients with atopic dermatitis. Acta Derm Venereol 1999; 79: 246-7
5. Pilgram GS, Vissers DC, van der Meulen H, et al. Aberrant lipid organization in stratum corneum of patients with atopic dermatitis and lamellar ichthyosis. J Invest Dermatol 2001; 117: 710-7
6. Macheleidt O, Kaiser HW, Sanshoff K. Deficiency of epidermal protein-bound omega-hydroxyceramides in atopic dermatitis. J Invest Dermatol 2002; 119: 166-73
7. Geilen CC, Wieder T, Orfanos CE. Ceramide signalling: regulatory role in cell proliferation, differentiation and apoptosis in human epidermis. Arch Dermatol Res 1997; 289 (10): 559-66
8. Burek C, Roth J, Koch HG, et al. The role of ceramide in receptor and stress-induced apoptosis studied in acidic ceramidase-deficient Farber disease cells. Oncogene 2001; 20: 6493-502
9. 2-induced apoptosis with acid sphingomyelinase activation. Biochim Biophys Acta 2001; 1533: 47-54
10. Separovic D, Mann KJ, Oleinick NL. Association of ceramide accumulation with photodynamic treatment-induced cell death. Photochem Photobiol 1998; 68: 101-9
11. Pena LA, Fuks Z, Kolesnick R. Stress-induced apoptosis and the sphingomyelin pathway. Biochem Pharmacol 1997; 53: 615-21
12. Kolesnick R. The therapeutic potential of modulating the ceramide/sphingomyelin pathway. J Clin Invest 2002; 110: 3-8
13. Ogretmen B, Hannun YA. Updates on functions of ceramides in chemotherapy-induced cell death and in multidrug resistance. Drug Resist Updat 2001; 4: 368-77
14. Claus R, Russwurm S, Meisner M, et al. Modulation of the ceramide level: a novel therapeutic concept? Curr Drug Targets 2000; 1: 185-205
15. Lucci A, Han TY, Liu YY, et al. Multidrug resistance modulators and doxorubicin synergize to elevate ceramide levels and elicit apoptosis in drug-resistant cancer cells. Cancer 1999; 86: 300-11
16. Charles AG, Han TY, Liu YY, et al. Taxol-induced ceramide generation and apoptosis in human breast cancer cells. Cancer Chemother Pharmacol 2001; 47: 444-50
17. Holleran WM, Feingold KR, Man MQ, et al. Regulation of epidermal sphingolipid synthesis by permeability barrier function. J Lipid Res 1991; 32 (7): 1151-8
18. Holleran WM, Takagi Y, Menon GK, et al. Permeability barrier requirements regulate epidermal β-glucocerebrosidase. J Lipid Res 1995; 35: 905-12
19. Jensen JM, Schütze S, Förl M, et al. Roles for tumor necrosis factor receptor p55 and sphingomyelinase in repairing the cutaneous permeability barrier. J Clin Invest 1999; 104: 1761-70
20. Higuchi K, Hara J, Okamoto R, et al. The skin of atopic dermatitis patients contains a novel enzyme, glucosylceramide sphingomyelin deacylase, which cleaves the N-acyl linkage of sphingomyelin and glucosylceramide. Biochem J 2000; 350: 747-56
21. Hara J, Higuchi K, Okamoto R, et al. High-expression of sphingomyelinase deacylase is an important determinant of ceramide deficiency leading to barrier disruption atopic dermatitis. J Invest Dermatol 2000; 115: 406-13
22. Ishibashi M, Arikawa J, Okamoto R, et al. Abnormal expression of the novel epidermal enzyme, glucosylceramide deacylase, and the accumulation of its enzymatic reaction product, glucosylsphingosine, in the skin of patients with atopic dermatitis. Lab Invest 2003; 83: 397-408
23. Wilkening G, Linke T, Sandhoff K. Lysosomal degradation on vesicular membrane surfaces. J Biol Chem 1998; 273: 30271-8
24. Tayama M, Soeda S, Kishimoto Y, et al. Effect of saposins on acid sphingomyelinase. Biochem J 1993; 290: 401-4
25. Hammond SA, Tsonis C, Sellins K, et al. Transcutaneous immunization of domestic animals: opportunities and challenges. Adv Drug Deliv Rev 2000; 43: 45-55
26. Ponec M, Weerheim A, Lankhorst P, et al. New acylceramide in native and reconstructed epidermis. J Invest Dermatol 2003; 120: 581-8
27. Bouwstra JA, Gooris GS, Dubbelaar FER, et al. Phase behavior of stratum corneum lipid mixtures based on human ceramides: the role of natural and synthetic ceramide 1. J Invest Dermatol 2002; 118: 606-17
28. Bouwstra JA, Gooris GS, Dubbelaar FER, et al. Phase behavior of lipid mixtures based on human ceramides: coexistence of crystalline and lipid phases. J Lipid Res 2001; 42: 1759-70
29. White SH, Mirejovsky D, King GI. Structure of lamellar lipid domains and corneocyte envelopes of murine stratum corneum: an x-ray diffraction study. Biochemistry 1988; 27: 3725-32
30. Bouwstra JA, Gooris GS, van der Spek JA, et al. Structural investigations of human stratum corneum by small-angle x-ray scattering. J Invest Dermatol 1991; 97: 1005-12
31. Bouwstra JA, Gooris GS, van der Spek JA, et al. The lipid and protein structure of mouse stratum corneum: a wide and small angle diffraction study. Biochim Biophys Acta 1994; 1212: 183-92
32. Pilgram GS, Engelsma-van Pelt AM, Bouwstra JA, et al. Electron diffraction provides new information on human stratum corneum lipid organization studied in relation to death and temperature. J Invest Dermatol 1999; 113: 403-9
33. Bouwstra JA, Honeywell-Nguyen PL. Skin structure and mode of vesicles. Adv Drug Deliv Rev 2002; 54: s41-55
34. Jin K, Higaki Y, Tagaki Y, et al. Analysis of beta-glucocerebrosidase and ceramidase activities in atopic and aged dry skin. Acta Derm Venereol 1994; 74: 337-40
35. Imokawa G, Akasaki S, Hattori M, et al. Selective recovery of deranged water-holding properties by stratum lipids. J Invest Dermatol 1986; 87: 758-61
36. Di Nardo A, Wertz P, Giannetti A, et al. Ceramide and cholesterol composition of the skin of patients with atopic dermatitis. Acta Derm Venereol 1998; 78: 27-30
37. Murata Y, Ogata J, Higaki Y, et al. Abnormal expression of sphingomyelin acylase in atopic dermatitis: an etiologic factor for ceramide deficiency? J Invest Dermatol 1996; 106: 1242-9
38. Yamamoto A, Serizawa S, Ito M, et al. Stratum corneum lipid abnormalities in atopic dermatitis. Arch Dermatol Res 1991; 283: 219-23
39. Ohnishi Y, Okino N, Ito M, et al. Ceramidase activity in bacterial skin flora as a possible cause of ceramide deficiency in atopic dermatitis. Clin Diagn Lab Immunol 1999; 6: 101-4
40. Kusuda S, Chang-Yi C, Takahashi M, et al. Localization of sphingomyelinase in lesional skin of atopic dermatitis patients. J Invest Dermatol 1998; 111: 733-8
41. Chang-Yi C, Kusuda S, Seguchi T, et al. Decreased level of prosaposin in atopic skin. J Invest Dermatol 1997; 109: 319-23
42. Jensen JM, Folster-Holst R, Baranowsky A, et al. Impaired sphingomyelinase activity and epidermal differentiation in atopic dermatitis. J Invest Dermatol 2004; 122 (6): 1423-31
43. Arikawa J, Ishibashi M, Kawashima M, et al. Decreased levels of sphingosine, a natural antimicrobial agent, may be associated with vulnerability of the stratum corneum from patients with atopic dermatitis to colonization by Staphylococcus aureus. J Invest Dermatol 2002; 119: 433-9
44. Okamoto R, Arikawa J, Ishibashi M, et al. Sphingosylphosphorylcholine is upregulated in the stratum corneum of patients with atopic dermatitis. J Lipid Res 2003; 44: 93-102
45. Uchida Y, Hara M, Nishio M, et al. Epidermal sphingomyelins are precursors for selected stratum corneum ceramides. J Lipid Res 2000; 41: 2071-82
46. Motta S, Monti M, Sesana S, et al. Abnormality of water barrier function in psoriasis: role of ceramide functions. Arch Dermatol 1994; 130: 452-6
47. Motta S, Sesana S, Monti M, et al. Interlamellar lipid difference between normal and psoriatic stratum corneum. Acta Derm Venereol Suppl 1994; 186: 131-2
48. Motta S, Monti M, Sesana S, et al. Ceramide composition of the psoriatic scale. Biochim Biophys Acta 1993; 1182: 147-51
49. Alessandrini F, Stachowitz S, Ring J, et al. The level of prosaposin is decreased in the skin of patients with psoriasis vulgaris. J Invest Dermatol 2001; 116: 394-400
50. Sidransky E, Fartasch M, Lee RE, et al. Epidermal abnormalities may distinguish type 2 from type 1 and type 3 of Gaucher disease. Pediatr Res 1996; 39: 134-41
51. Holleran WM, Ginns EI, Menon GK, et al. Consequences of β-glucocerebrosidase deficiency in epidermis: ultrastructure and permeability barrier alterations in Gaucher disease. J Clin Invest 1994; 93 (4): 1756-64
52. Doering T, Proia RL, Sandhoff K. Accumulation of protein-bound epidermal glucosylceramides in β-glucocerebrosidase deficient type 2 Gaucher mice. FEBS Lett 1999; 447: 167-70
53. Orbisky E, Sidransky E, McKinney CE, et al. Glucosylsphingosine accumulation in mice and patients with type 2 Gaucher disease begins early in gestation. Pediatr Res 2000; 48: 233-7
54. Ida H, Rennert OM, Eto Y, et al. Cloning of a human acid sphingomyelinase cDNA with a new mutation that renders the enzyme inactive. J Biochem 1993; 114: 15-20
55. Schmuth M, Man MQ, Weber F, et al. Permeability barrier disorder in Niemann-Pick disease: sphingomyelin-ceramide processing required for normal barrier homeostasis. J Invest Dermatol 2000; 115: 459-66
56. Muramatsu T, Sakai N, Yanagihara I, et al. Mutation analysis of the acid ceramidase gene in Japanese patients with Farber disease. J Inherit Metab Dis 2002; 25: 585-92
57. De Paepe K, Roseeuw D, Rogiers V. Repair of acetone- and sodium lauryl sulfate-damaged human skin barrier function using topically applied emulsions containing barrier lipids. J Eur Acad Dermatol Venereol 2002; 16: 587-94
58. Coderch L, De Pera M, Fonollosa J, et al. Efficacy of stratum corneum lipid supplementation on human skin. Contact Dermatitis 2002; 47: 139-46
59. Man MM, Feingold KR, Thornfeldt CR, et al. Optimization of physiological lipid mixtures for barrier repair. J Invest Dermatol 1996; 106: 1096-101
60. Berardesca E, Barbareschi M, Veraldi S, et al. Evaluation of efficiency of a skin lipid mixture in patients with irritant contact dermatitis, allergic contact dermatitis or atopic dermatitis: a multicenter study. Contact Dermatitis 2001; 45: 280-5
61. Kucharekova M, Schalkwijk J, van de Kerkhof PCM, et al. Effect of a lipid-rich emollient containing ceramide 3 in experimentally induced skin barrier dysfunction. Contact Dermatitis 2002; 46: 331-8
62. Chamlin SL, Kao J, Frieden IJ, et al. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol 2002; 47: 198-208